Table 6.
Univariate analysis of predictive factors for combined OTR and PFS in patients with mCRC treated with FOLFOX-based chemotherapy
| Variables | N | gOTR/lPFS (%) | Non-gOTR/lPFS (%)a | P value |
|---|---|---|---|---|
| Primary tumor site | ||||
| Colon | 55 | 20 (36) | 35 (64) | 0.11 |
| Rectum | 24 | 4 (17) | 20 (83) | |
| Histological classification | ||||
| Well/moderate | 75 | 22 (29) | 53 (71) | 0.58 |
| Poor/mucinous | 4 | 2 (50) | 2 (50) | |
| Depth of invasion | ||||
| pT2/pT3 | 41 | 8 (20) | 22 (80) | 0.05 |
| pT4 | 38 | 16 (42) | 33 (58) | |
| Lymph node metastasis | ||||
| pN0/pN1 | 44 | 14 (32) | 30 (68) | 0.81 |
| pN2 | 35 | 10 (29) | 25 (71) | |
| Lymphatic invasion | ||||
| ly0/ly1 | 18 | 6 (33) | 12 (67) | 0.78 |
| ly2/ly3 | 61 | 18 (30) | 43 (70) | |
| Venous invasion | ||||
| v0/v1 | 21 | 6 (29) | 15 (71) | 1.00 |
| v2/v3 | 58 | 18 (31) | 40 (69) | |
| OAT2/OCT2 | ||||
| High/high | 18 | 11 (61) | 7 (39) | 0.003c |
| Non-high/highb | 61 | 13 (21) | 48 (79) |
a
Patients with unfavorable outcomes of at least one of OTR and PFS.
b
Tumors with low levels of at least one of OAT2 and OCT2.
c
Statistically significant.
This analysis was evaluable in 79 of the 90 patients. FOLFOX: 5-fluorouracil/leucovorin/oxaliplatin; gOTR/lPFS: good OTR/long PFS; mCRC: metastatic colorectal cancer; OAT2: organic anion transporter 2; OCT2: organic cation transporter 2; OTR: objective tumor response; PFS: progression-free survival.